Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease

Study Met its Primary Endpoint
GENEVA, October 25, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that the two-year Phase III REFLEX 1 study met its primary
endpoint by demonstrating that Rebif(R) (interferon beta-1a) significantly
delayed conversion to multiple sclerosis (MS) diagnosed according to the
McDonald criteria 2 in patients with a first clinical … Read more »».

Non-communicable Diseases Mortality to Cost a Whopping USD237 Billion to the National Income by 2015

Experts Say Universal Access to Preventive and Curative Intervention is Crucial

NEW DELHI, October 25, 2010 – Health experts participating at a roundtable organised by India Health
Progress(IHP) on economic and social impact of non-communicable diseases in
India are of the opinion that a concerted effort is required to address the
growing burden.
A review …. Original article  : Non-communicable Diseases Mortality to Cost a Whopping USD237 Billion to the National Income by 2015.

MarketsandMarkets New Report – Global Ophthalmology Drugs & Devices Market

DALLAS, October 25, 2010 – Read The Complete TOC Here:
www.marketsandmarkets.com/Market-Reports/ophthalmology-drugs-devices-2
18.html

Global ophthalmology drug and devices market is witnessing a significant
growth due to the increasing incidence and prevalence of eye related
disorders such as presbyopia, macular degeneration, and diabetic retinopathy
among the aging population. With the introduction of ophthalmic devices
equipped with sophisticated technologies, people … Original source on Gaea Times at : MarketsandMarkets New Report – Global Ophthalmology Drugs & Devices Market.

Elsevier Introduces Protein Viewer, Bringing Science to Life

New Feature on SciVerse ScienceDirect Presents Proteins in Three Dimensions, Allowing Manipulation of Molecular Structures, to the Benefit of the Reader

AMSTERDAM, October 25, 2010 – Elsevier, a world-leading publisher of scientific, medical and technical
products and services, introduces Protein Viewer, a new, interactive feature
on SciVerse ScienceDirect for the Journal of Molecular Biology (JMB)
(www.sciencedirect.com/science/journal/00222836). With Protein … Original article on : Elsevier Introduces Protein Viewer, Bringing Science to Life.

Positive Results From LigoCyte’s Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting

Intranasal Norovirus VLP Vaccine Demonstrates Clinical Efficacy When Compared to Placebo in Phase I/II Trial

BOZEMAN, Montana, October 25, 2010 – LigoCyte Pharmaceuticals, Inc., a private, clinical-stage
biopharmaceuticals company developing innovative vaccine products, today
announced positive results from a Phase I/II challenge study of its norovirus
virus-like particle (VLP) vaccine candidate. Baylor College of Medicine's
Robert Atmar, M.D., the …. Read the original article  : Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting.

Infosys Science Foundation Announces Winners of the Infosys Prize 2010

Winners to be Awarded Rs.50 lakh in Recognition of Their Outstanding Contributions to Scientific Research

BANGALORE, India, October 25, 2010 – The Infosys Science Foundation today announced the winners of
the Infosys Prize 2010 recognizing outstanding contributions to scientific
research that have impacted India. The winners across five categories -
Mathematical Sciences, Physical Sciences, Engineering and Computer Science,
Life …. Source  : Infosys Science Foundation Announces Winners of the Infosys Prize 2010.